GeoVax Labs Inc is a biotechnology company committed to developing innovative immunotherapies for preventing and treating infectious diseases such as HIV/AIDS. Their corporate philosophy revolves around advancing global public health by leveraging their expertise in vaccine research and development. With a focus on creating novel vaccines and immunotherapies, GeoVax Labs Inc aims to make a positive impact on society. By combining cutting-edge science and a dedication to improving the lives of patients worldwide, GeoVax Labs Inc remains committed to delivering effective solutions to combat infectious diseases and enhance the quality of life for individuals around the world.

GeoVax Labs Inc is primarily present in the United States. The company is headquartered in Atlanta, Georgia and operates mainly within the United States market.

GeoVax Labs Inc., a prominent biotechnology company, has achieved several significant milestones. Firstly, they successfully developed multiple vaccine candidates, including vaccines against HIV, Ebola, and Zika viruses. Furthermore, their vaccine platform technology has shown promising results in clinical trials, demonstrating its potential in preventing and treating infectious diseases. Moreover, GeoVax Labs Inc. has obtained funding from various governmental agencies and organizations, recognizing the importance and potential of their innovative research. Additionally, the company has formed key collaborations with world-renowned institutions and industry leaders, further enhancing their expertise and expanding their research capabilities. GeoVax Labs Inc.'s remarkable achievements illustrate their commitment to advancing public health through groundbreaking vaccine development.

GeoVax Labs Inc, established in 2001, is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases, including HIV/AIDS and Zika virus. The company has built a robust pipeline of vaccine candidates based on its unique Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) platform. Through strategic collaborations and partnerships, GeoVax Labs Inc has made significant advancements in the field of vaccine development. With a dedication to scientific excellence and a strong emphasis on research and development, GeoVax Labs Inc continues to make strides in its mission to deliver safe and effective vaccines to address global health challenges.

The main competitors of GeoVax Labs Inc in the market are companies such as Vaxart Inc, Inovio Pharmaceuticals Inc, and Moderna Inc.

GeoVax Labs Inc is primarily active in the biotechnology industry.

The business model of GeoVax Labs Inc focuses on the development and commercialization of vaccines to prevent infectious diseases. With a particular focus on HIV/AIDS, GeoVax utilizes its expertise in virology and immunology to develop novel vaccine candidates. The company's strategy involves collaborations with government agencies, research institutes, and other organizations to advance its clinical development programs. By leveraging its patented vaccine technology, GeoVax aims to address the global healthcare challenges associated with infectious diseases, including HIV/AIDS.

Det GeoVax Labs P/E-forhold er -0,09.

GeoVax Labs KUV er 2,64.

AlleAktien Kvalitetsscore for GeoVax Labs er 4/10.

Den forventede GeoVax Labs omsætning er 2,03 mio. USD.

Den forventede GeoVax Labs indtjening er -58,26 mio. USD.

GeoVax Labs Inc is a leading biotechnology company specializing in the research and development of vaccines for infectious diseases. The company was founded in 2001 and is headquartered in Atlanta, Georgia. GeoVax's business model is based on the development of vaccine candidates based on its proprietary MVA vector platform. This platform consists of a modified Vaccinia virus Ankara (MVA) that serves as a carrier of foreign genes to trigger an immune response against the target protein. GeoVax has several vaccine candidates in development, including vaccines against HIV, Ebola, and Zika. The HIV vaccine candidate has shown promising results in clinical trials, and the company has conducted a Phase IIa study in collaboration with the HIV Vaccine Trials Network. The company is also working on a combination therapy of HIV vaccine and antibody therapy. In addition, GeoVax has also developed an innovative technology platform called "Therapeutic Logic". This platform is based on the MVA virus's ability to infect cells and produce foreign proteins within them. The foreign proteins can have specific targets such as cancer cells or viral infections. By using foreign proteins as tumor antigens or antigens from infected cells, the body's immune reaction against these cells can be enhanced. This technology can be used for the development of new cancer therapies or improving existing therapies. GeoVax also has an early pipeline of therapeutics against infectious diseases, including hepatitis B and C, Lassa fever, and SARS-CoV-2. The company collaborates with leading academic and industry partners to further develop its technologies and products. As part of its business model, GeoVax has also entered into partnerships and licensing agreements to distribute its technologies and products worldwide. For example, the company has partnered with the University of Pittsburgh Medical Center to utilize its Therapeutic Logic technology for the development of novel cancer therapies. In summary, GeoVax Labs Inc is an innovative biotechnology company focused on the development of vaccines and therapeutics for infectious diseases and cancer. The company has a broad and promising pipeline of products and technologies in development and works closely with academic and industry partners to expand its reach and capabilities.

GeoVax Labs udbetaler et udbytte på 0 USD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for GeoVax Labs, eller selskabet udbetaler ikke udbytte.

ISIN'en for GeoVax Labs er US3736785078.

WKN for GeoVax Labs er A2QERV.

Tickeren for GeoVax Labs er GOVX.

I løbet af de sidste 12 måneder betalte GeoVax Labs en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil GeoVax Labs sandsynligvis betale en dividende på 0 USD.

Udbytteafkastet for GeoVax Labs er i øjeblikket .

GeoVax Labs betaler kvartalsvis udbytte. Dette uddeles i månederne .

GeoVax Labs betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 USD. Dette svarer til et dividendeafkast på 0 %.

GeoVax Labs bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på GeoVax Labs fra den 22.9.2024 på 0 USD, skulle du have haft aktien i din portefølje før ex-datoen den 22.9.2024.

Udbetalingen af det sidste udbytte blev foretaget den 22.9.2024.

I løbet af 2023 udbetalte GeoVax Labs 0 USD i form af dividender.

Udbytterne fra GeoVax Labs udbetales i USD.